We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA, pharmaceutical companies and device manufacturers are looking to close the lag time between approvals of new antibiotics and 510(k) clearance of related antimicrobial susceptibility tests, which assist clinicians in determining which drug and dosage to select for treatment. Read More
Windtree Therapeutics received a Fast Track designation from FDA for its Aerosurf (lucinactant for inhalation) aerosol treatment for premature infants with respiratory distress syndrome. Read More